StockNews.com upgraded shares of DaVita (NYSE:DVA – Get Rating) from a buy rating to a strong-buy rating in a report published on Friday morning.
A number of other equities research analysts have also weighed in on DVA. Truist Financial upped their target price on shares of DaVita from $114.00 to $125.00 and gave the stock a hold rating in a report on Wednesday, January 5th. Zacks Investment Research upgraded shares of DaVita from a sell rating to a hold rating and set a $121.00 target price on the stock in a report on Tuesday, January 4th. Six analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of Hold and an average target price of $133.00.
DVA opened at $121.45 on Friday. DaVita has a 1-year low of $94.38 and a 1-year high of $136.48. The company has a current ratio of 1.32, a quick ratio of 1.28 and a debt-to-equity ratio of 9.32. The company has a market cap of $11.70 billion, a P/E ratio of 13.68, a price-to-earnings-growth ratio of 1.47 and a beta of 1.18. The company has a fifty day moving average price of $114.06 and a two-hundred day moving average price of $110.67.
DaVita (NYSE:DVA – Get Rating) last posted its earnings results on Thursday, February 10th. The company reported $2.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.22. DaVita had a net margin of 8.42% and a return on equity of 77.78%. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.91 billion. During the same quarter in the prior year, the business posted $1.67 EPS. The firm’s revenue was up 1.3% compared to the same quarter last year. On average, research analysts forecast that DaVita will post 8.09 EPS for the current fiscal year.
In other DaVita news, Director Paula A. Price sold 700 shares of the stock in a transaction dated Monday, February 14th. The shares were sold at an average price of $113.64, for a total value of $79,548.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.00% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in DVA. Johnson Financial Group Inc. bought a new position in shares of DaVita during the 4th quarter valued at approximately $27,000. CI Investments Inc. bought a new position in shares of DaVita during the 3rd quarter valued at approximately $34,000. Monolith Advisors bought a new position in shares of DaVita during the 4th quarter valued at approximately $51,000. Cullen Frost Bankers Inc. bought a new position in shares of DaVita during the 4th quarter valued at approximately $74,000. Finally, First Community Trust NA bought a new position in shares of DaVita during the 4th quarter valued at approximately $91,000. 84.28% of the stock is owned by hedge funds and other institutional investors.
About DaVita (Get Rating)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
Receive News & Ratings for DaVita Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DaVita and related companies with MarketBeat.com’s FREE daily email newsletter.
from WordPress https://ift.tt/3PjHQJn
via IFTTT
No comments:
Post a Comment